116 related articles for article (PubMed ID: 10595366)
1. In vitro and in vivo delivery of antisense oligodeoxynucleotides using lipofection: application of antisense technique to growth suppression of experimental glioma.
Matsuno A; Nagashima T; Katayama H; Tamura A
Methods Enzymol; 2000; 313():359-72. PubMed ID: 10595366
[No Abstract] [Full Text] [Related]
2. An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro.
Sugawa N; Ueda S; Nakagawa Y; Nishino H; Nosaka K; Iwashima A; Kurimoto M
J Neurooncol; 1998 Sep; 39(3):237-44. PubMed ID: 9821109
[TBL] [Abstract][Full Text] [Related]
3. Polyethyleneimine-mediated transfection to improve antisense activity of 3'-capped phosphodiester oligonucleotides.
Dheur S; Saison-Behmoaras TE
Methods Enzymol; 2000; 313():56-73. PubMed ID: 10595349
[No Abstract] [Full Text] [Related]
4. Preparation and application of liposome-incorporated oligodeoxynucleotides.
Tari AM
Methods Enzymol; 2000; 313():372-88. PubMed ID: 10595367
[No Abstract] [Full Text] [Related]
5. c-Met antisense oligodeoxynucleotides increase sensitivity of human glioma cells to paclitaxel.
Chu SH; Ma YB; Feng DF; Zhang H; Qiu JH; Zhu ZA
Oncol Rep; 2010 Jul; 24(1):189-94. PubMed ID: 20514461
[TBL] [Abstract][Full Text] [Related]
6. In vitro transport and delivery of antisense oligonucleotides.
Hughes J; Astriab A; Yoo H; Alahari S; Liang E; Sergueev D; Shaw BR; Juliano RL
Methods Enzymol; 2000; 313():342-58. PubMed ID: 10595365
[TBL] [Abstract][Full Text] [Related]
7. Selective transvascular delivery of oligodeoxynucleotides to experimental brain tumors.
Koga H; Inamura T; Ikezaki K; Samoto K; Matsukado K; Fukui M
J Neurooncol; 1999 Jun; 43(2):143-51. PubMed ID: 10533726
[TBL] [Abstract][Full Text] [Related]
8. Disruption of mRNA-RNP formation and sorting to dendritic synapses by antisense oligodeoxynucleotides.
Jakoi ER; Severt WL
Methods Enzymol; 2000; 313():456-66. PubMed ID: 10595373
[No Abstract] [Full Text] [Related]
9. Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth.
Tang P; Jasser SA; Sung JC; Shi Y; Steck PA; Yung WK
J Neurooncol; 1999 Jun; 43(2):127-35. PubMed ID: 10533724
[TBL] [Abstract][Full Text] [Related]
10. Cell-specific optimization of phosphorothioate antisense oligodeoxynucleotide delivery by cationic lipids.
Williams SA; Buzby JS
Methods Enzymol; 2000; 313():388-97. PubMed ID: 10595368
[No Abstract] [Full Text] [Related]
11. 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) for effective antisense formation.
Morita K; Yamate K; Kurakata S; Watanabe K; Imanishi T; Koizumi M
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1619-21. PubMed ID: 14565480
[TBL] [Abstract][Full Text] [Related]
12. A cytosine analog that confers enhanced potency to antisense oligonucleotides.
Flanagan WM; Wolf JJ; Olson P; Grant D; Lin KY; Wagner RW; Matteucci MD
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3513-8. PubMed ID: 10097067
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
[TBL] [Abstract][Full Text] [Related]
14. Specific gene suppression using antisense strategy for growth suppression of glioma.
Matsuno A; Nagashima T
Med Electron Microsc; 2004 Sep; 37(3):158-61. PubMed ID: 15449107
[TBL] [Abstract][Full Text] [Related]
15. Efficient transfer of intact oligonucleotides into the nucleus of ligament scar fibroblasts by HVJ-cationic liposomes is correlated with effective antisense gene inhibition.
Nakamura N; Hart DA; Frank CB; Marchuk LL; Shrive NG; Ota N; Taira K; Yoshikawa H; Kaneda Y
J Biochem; 2001 May; 129(5):755-9. PubMed ID: 11328598
[TBL] [Abstract][Full Text] [Related]
16. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
17. Basic principles of using antisense oligonucleotides in vivo.
Phillips MI; Zhang YC
Methods Enzymol; 2000; 313():46-56. PubMed ID: 10595348
[No Abstract] [Full Text] [Related]
18. [Inhibitory effect of cationic liposome-mediated antisense c-myb oligonucleotide on the growth of glioma].
Zhao D; You C; Huang G; Liao X; Tan H
Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):19-22. PubMed ID: 12599418
[TBL] [Abstract][Full Text] [Related]
19. Cationic liposomes/lipids for oligonucleotide delivery: application to the inhibition of tumorigenicity of Kaposi's sarcoma by vascular endothelial growth factor antisense oligodeoxynucleotides.
Lavigne C; Lunardi-Iskandar Y; Lebleu B; Thierry AR
Methods Enzymol; 2004; 387():189-210. PubMed ID: 15172165
[No Abstract] [Full Text] [Related]
20. Chimeric oligodeoxynucleotide analogs: chemical synthesis, purification, and molecular and cellular biology protocols.
Giles RV; Spiller DG; Tidd DM
Methods Enzymol; 2000; 313():95-135. PubMed ID: 10595351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
